Analysts say that US antitrust regulators could force the firms to shed some overlapping stent operations.

The move by Johnson & Johnson has been widely expected and the firm will pay $76 for each Guidant share, 6% more than Wednesday's closing price.

A number of Johnson & Johnson's products are facing patent expirations, while the company is also battling fierce competition from generic products.

Analysts said that the deal is aimed at offsetting Johnson & Johnson's reliance on a slowing drug business.

Meanwhile, demand for defibrillators, which give the heart a small electric shock when an irregular heartbeat or rhythm is detected, is expected to increase, analysts said.

